We report here the cases of two females with Graves' disease who developed insulin autoimmune syndrome after treatment with methimazole. The patients exhibited a sudden altered mental state after treatment with methimazole for approximately 4 weeks. Patients had hypoglycemia with serum glucose below 70 mg/dL, and laboratory findings showed both high levels of serum insulin and high titers of in...

background and objectives this study was undertaken to evaluate the effect of the cultivated satureja khuzestanica essential oil (skeo) on activity and gene expression of hepatic gk in normal and diabetic rats.   methods biochemical parameters such as glucose, insulin, and hba1c plasma levels and oral glucose tolerance test were all analyzed. the cultivated skeo was orally administered at diffe...

The recent discoveries in the fields of pathogenesis and management of diabetic nephropathy have revolutionized the knowledge about this disease. Little was added to the management of diabetic nephropathy after the introduction of renin angiotensin system blockers. The ineffective role of the renin- angiotensin system blockers in primary prevention of diabetic nephropathy in type 1 diabetes mel...

Introduction: Chronic kidney disease (CKD) poses a financial burden on most patients from low/ middle income countries. Glycaemic control with affordable hypoglycemic agents may influence the prognosis of diabetic nephropathy. Objectives: We aimed to compare rates CKD progression and proteinuria in type 2 population response use various agents. Patients Methods: A retrospective cross-sectional ...

Cuscuta reflexa (whole plant) and Calotropis procera (leaves) are used in folk medicine of Bangladesh to control blood sugar in patients suffering from diabetes mellitus. The hypoglycemic effects of methanol and chloroform extracts of whole plants of Cuscuta reflexa, and methanol extract of leaves of Calotropis procera were investigated in oral glucose tolerance tests in Long Evans rats and Swi...

Background: New noninsulin hypoglycemic agents, the incretin and amylin groups, are available to treat patients with type 2 diabetes and inadequate glucose control with the regular routinely used agents, namely metformin or sulfonylurea. Incretin therapies are based on the release of intestinal peptides (glucagon-like peptide 1) in the presence of glucose in the gut which stimulates insulin sec...